- Motif Bio has received the official meeting minutes from the U.S. Food and Drug Administration (FDA) guidance meeting which was held on 14 April 2015.

The minutes confirm the FDA's agreement with Motif's Phase III clinical development programme for iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria.

Iclaprim, a novel selective inhibitor of microbial dihydrofolate reductase (DHFR), is being developed as an intravenous (IV) formulation to treat acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) caused by Gram positive pathogens, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP).

The FDA has confirmed that two successful Phase III trials are required for the approval of iclaprim.

At 9:39am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +1.25p at 34.25p

Story provided by